

Drug Sales Report (Top/Bottom Analysis)

Month

Apr

Year

All

COGS in Apr

\$1.08M

Mar : 1,162,315

Variance: ▼ -7.3%

Quantity in Apr

23K

Mar : 23,284

Variance: ▲ +0.1%

Revenue in Apr

\$6.02M

Mar : 6,088,678

Variance: ▼ -1.1%

Profit in Apr

\$4.94M

Mar : 4,926,363

Variance: ▲ +0.4%

Profit Margin in Apr

82.11%

Mar: ▲ +80.9%

Top

Bottom

5

29.9% of (\$)Profit is from the
Top-5 Drugs

5-Top Performing Drugs by (\$)Profit

Active Measure

#Transactions

Profit

Revenue

Unit Sold

Lisinopril

0.36M

Doxycycline

0.35M

Levothyroxine

0.28M

Insulin Glargine

0.26M

Valacyclovir

0.23M

14,78,167 out of 49,43,807 of Profit

Bottom

Top

4.5% of (\$)Profit is from Least
Sold 5 Customer

5-Under Performing Customer by (\$)Profit

Alice Brown

61K

Jane Williams

59K

Jane Smith

42K

Carol Jones

30K

Carol Smith


28K

17,95,625 out of 49,43,807 of Profit

Drug Sales Report

(Customer Analysis)

Revenue by Buyer Type




#Customers
200


Avg Revenue
357K

Total Revenue
\$71.31M

Revenue by Gender




Revenue by Country



65.80 % of revenue share is attributed to Canada and Australia

Revenue by Age-Group



68.69% of revenue share is attributed to 51 + and 31-40